Outcomes of esophagectomy after noncurative endoscopic resection of early esophageal cancer

Solène Dermine, Mahaut Leconte, Sarah Leblanc, Bertrand Dousset, Benoit Terris, Arthur Berger, Anne Berger, Gabriel Rahmi, Vincent Lepilliez, Olivier Plomteux, Philippe Leclercq, Romain Coriat, Stanislas Chaussade, Frédéric Prat and Maximilien Barret

Abstract

Background: Current guidelines recommend performing esophagectomy after endoscopic resection for early esophageal cancer when the risk of lymph node metastasis or residual cancer is found to be significant and endoscopic treatment is therefore noncurative. Our aim was to assess the safety and oncological outcomes of esophagogastric resection in this specific clinical setting.

Patients and methods: A retrospective review from 2012 to 2018 was performed at four tertiary referral centers. All patients had a noncurative endoscopic resection of a clinical T1 esophageal cancer, followed by esophagectomy. Outcome measures were the rates of T0N0 specimens, overall survival, disease-free and cancer-specific survival, postoperative morbidity and mortality.

Results: A total of 30 patients (13 with squamous cell carcinoma and 17 with adenocarcinoma) were included. The reasons for noncurative endoscopic resection were: positive vertical margins (n = 12), squamous cell carcinoma with muscularis mucosae or submucosal layer invasion (n = 3 and 9), adenocarcinoma with deep submucosal invasion (n = 11), poorly differentiated tumor (n = 6) and lymphovascular invasion (n = 6). Overall, 63% of the esophagi were T0N0; most residual lesions were T1a metachronous lesions, and four (13%) patients had advanced pT status (n = 3) or lymph node metastases (n = 2). Overall survival, disease-free survival and cancer-specific survival were 83%, 75%, and 90% respectively. A total of 43% of patients had severe postoperative complications, and postoperative mortality was 7%.

Conclusion: In this cohort, esophagectomy allowed the resection of residual advanced cancer or lymph node metastases in 13% of cases, at the cost of 43% severe morbidity and 7% mortality. Therefore, the possibility of close follow up needs to be balanced with a highly morbid surgical management in these patients.

Keywords: endoscopic mucosal resection, endoscopic submucosal dissection, esophageal adenocarcinoma, esophageal squamous cell carcinoma, esophagectomy, superficial esophageal cancer

Received: 25 April 2019; revised manuscript accepted: 11 November 2019.
Considering the risk of lymph node metastasis, esophagectomy is recommended in cases of noncurative endoscopic resection in the esophagus. The first criteria to define noncurative endoscopic resection is the deepest intramural tumor extension. For SCC, the risk of lymph node metastasis ranges from 8% to 19% for lesions invading the muscularis mucosae (m3) or the submucosal layer below 200 μm and 30–54% for lesions invading the deep submucosa. For EAC, the risk is nil for mucosal lesions, 5–6% for lesions invading the submucosal layer below 500 μm and 19–21% for lesions invading the deep submucosa. The other criteria to define a noncurative endoscopic resection are a poorly differentiated tumor, or the presence of lymphovascular invasion, increasing the risk of lymphovascular involvement 4.04–9.73 and 35.8 respectively. Finally, the curative endoscopic resection of an early esophageal cancer implies an en bloc and histologically complete resection of a well to moderately differentiated lesion, with no lymphovascular invasion, limited to the shallow submucosa (for EAC) or the lamina propia (for SCC). Esophagectomy and lymph node dissection leads to major complications in up to 40% of patients, and mortality in up to 10%. Most studies reporting on the outcomes of esophagectomy include patients with stage I and II diseases, with a small proportion of T1 lesions. Furthermore, the inclusion of patients after neoadjuvant treatment might overestimate the adverse event rates after esophagogastric surgical resection.

This study aims to assess the outcomes of esophagectomy after noncurative endoscopic resection, in terms of pathology results, safety, and survival.

Patients and methods

Patients

This was a retrospective study performed at four French and Belgian tertiary referral centers for therapeutic endoscopy from 2012 to 2018. All patients had a T1 esophageal cancer with a noncurative endoscopic resection, followed by esophagectomy. Surgery was indicated by a multidisciplinary meeting involving gastrointestinal endoscopists, oncologists, surgeons, pathologists, radiotherapists and radiologists. Data were collected from the patients’ medical files, endoscopy and pathology reports.

The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki and has been approved by the ethical review committee for publications of the Cochin University Hospital (CLEP decision no. AAA-2018-08013) on 18 October 2018. All patients provided written informed consents for the endoscopic procedures and surgery.

Endoscopic resections

All endoscopic procedures were performed by experienced operators. Endoscopic mucosal resection was performed for SCC smaller than 10 mm and for Paris 0–IIa and 0–IIb EAC, that is, without endoscopic suspicion of deep submucosal invasion. Endoscopic submucosal dissection was performed for lesions larger than 10 mm for SCC, or when protruding or depressed features where found in EAC (Paris 0–Is and 0–IIc).

All resections were performed en bloc.

Histological analysis and indication for surgery

Resected specimens were pinned on polystyrene boards and fixed in 10% formalin for 24h. After fixation, specimens were cut into 2–3-mm slices and embedded in paraffin. Blocks were further sliced at 4 μm and stained with hematoxylin–eosin–safron. The following data were assessed: histological type, grade of differentiation, invasion of the lateral or vertical margins, deepest tumor extension (mucosal or submucosal invasion), and presence of lymphovascular involvement. The length of the tumor was not considered. R0 resection was defined as an en bloc resection, with horizontal and vertical margins free of cancer. In cases of submucosal invasion, the depth of the tumor from the muscularis mucosae was measured. Curative endoscopic resection was defined as a R0 resection without deep mural infiltration or poor histoprognostic factors, as defined by the ESGE guidelines: absence of poorly differentiated cancer, absence of lymphovascular involvement and absence of...
S Dermine, M Leconte et al.

**Deep invasion:** mucosal m3 or submucosal invasion for SCC and >500 µm submucosal invasion for EAC.22

**Surgical treatment**

Open esophagectomy or minimally invasive esophagectomy were performed, under general anesthesia with endotracheal intubation, with intraoperative thoracic epidural analgesia. Esophagectomy and lymph node resection were performed by right transthoracic/Ivor Lewis, transthiatal or tri-incisional/McKeown techniques, according to the tumor localization and the surgeon’s choice.23,24 Cervical approach was performed above 25 cm and thoracic approach was performed below 25 cm. Extended total gastrectomy was used for Siewert II EAC in patients with major comorbid conditions. Histological examination of the surgical resection was performed by an expert pathologist and defined according to the pathologic TNM (pTNM) classification (AJCC 8th edition). Surgical complications were defined according to the Clavien–Dindo classification,25 at day 30 and day 90.19

**Follow up**

Patients were followed up with physical examination, blood tests, upper endoscopy and a thoraco-abdomino-pelvic computed tomography (CT) scan every 3 months for the first year and every 6 months for 5 years. Local recurrence was defined as a positive biopsy in the bed of the native esophagus. Metastatic recurrence was defined as the appearance of metastatic lesions with or without hypermetabolism on a positron emission tomography (PET)-CT scanner, in the distant organs or lymphadenopathies.

**Statistical analysis**

The main outcome measure was the rate of cancer-free surgical resection specimens. Secondary outcome measures were the rate of postoperative complications, including perioperative mortality and the overall survival, disease-free survival, and cancer-specific survival. Data were presented as median (range), and percentage. The overall survival rate was calculated from the date of surgery until relapse or death related to cancer. All statistical analyses were performed using the R Studio statistical software (version 3.4.4).

**Results**

**Patient characteristics**

A total of 30 patients (13 with esophageal SCC and 17 with EAC) with a median age of 65 years were included. There were 20 men and 10 women. Tumors were localized in the mid and lower esophagus for 15 patients in each category. The main patient characteristics are presented in Table 1.

**Histological characteristics of the lesions resected endoscopically**

Among the 13 patients with SCC, 11 tumors were well or moderately differentiated, and 2 were poorly differentiated. The depth of tumor invasion was: m2 in one patient, m3 in three patients, and deep submucosal invasion in nine patients. Lymphovascular invasion was observed in one patient. Histologically complete (R0) resection was performed in eight patients (62%). For the other cases, the vertical margin was positive in three patients, and impossible to assess (Rx) in two patients.

Among the 17 patients with EAC, 13 tumors were well or moderately differentiated, and 4 were poorly differentiated. The depth of tumor invasion was: m2 in 1 patient, m3 in 1 patient, m4 in 2 patients, superficially invading the submucosa (<500 µm) in 3 patients and deeply invading the submucosa in 11 patients. Lymphovascular invasion was observed in five patients. R0 resection was performed in five patients (29.4%). For the other patients, the lateral margins were positive in two patients, the vertical margin was positive in nine patients and the quality of the resection was not evaluable for one patient (Rx).

The reasons for noncurative endoscopic resection were: positive vertical margins (n = 12), SCC invading the muscularis mucosae (n = 3) or the submucosal layer (n = 9), EAC invading the submucosal layer beyond 500 µm (n = 11), poorly differentiated tumors (n = 6) and presence of lymphovascular invasion (n = 6). In 15 (50%)
cases, tumors exhibited more than one poor histoprognostic factor. These criteria are detailed in Table 2.

### Histological characteristics of the esophagectomy specimen

Surgical techniques were transthoracic esophagectomy ($n = 18$), transhiatal esophagectomy ($n = 5$), McKeown esophagectomy ($n = 3$) and extended total gastrectomy ($n = 4$).

A total of 60% of patients had an open esophagectomy and 40% had a minimally invasive esophagectomy. The lymph node harvest [median (range)] was 18 (9–29).

The median time [interquartile range (IQR)] between endoscopic resection and surgery was 90 days (55–112).

All patients had macroscopically and histologically complete resection (R0) of all neoplasia by esophagectomy. Overall, 11 (37%) patients had residual cancer on the surgical specimen: 9 with local residual tumor only, 1 with lymph node involvement only and 1 with both. Table 3 shows the detailed histological characteristics of the esophagectomy specimen with residual cancer. Only 2 of 30 (7%) patients had lymph node involvement on the surgical specimen: 1 EAC with a positive vertical margin and residual cancer on the resection site, and 1 SCC with deep submucosal invasion on the endoscopic specimen but no residual cancer on the resection site.

### Oncological outcomes

We diagnosed two distant cancer recurrences (mediastinal lymph nodes and lung metastases) during a median (IQR) follow up of 15 (8–37) months. The patient with lung metastases developed a recurrence 24 months after surgery for an incompletely resected T1b EAC with residual tumor and lymph node involvement on the surgical specimen (Table 3). The patient with mediastinal lymph nodes was diagnosed with disease recurrence 33 months after surgery and had an incompletely resected T1b EAC with deep submucosal invasion and residual tumor without lymph node involvement on the surgical specimen (Table 3).

No local recurrence was diagnosed. There were five deaths during the follow up: two postoperative inhospital deaths, one caused by aspiration pneumonia due to a postoperative esophageal stricture 16 months after surgery, one death related to cancer recurrence and one noncancer-related death. At the end of the follow up, overall survival, disease-free survival and cancer-specific survival were 83%
### Table 2. Criteria for surgery (noncurative endoscopic resection) for each patient according to the European Society of Gastrointestinal Endoscopy guidelines.

| Patients | Histology | Quantitative criteria | Qualitative criteria | Number of criteria |
|----------|-----------|-----------------------|----------------------|-------------------|
|          |           | Positive vertical margin | Invasion | Deep submucosal invasion, µm | Poor differentiation | Lymphovascular invasion | Budding (grade 2 or 3) | |
| 1        | SCC       | - | sm<sup>b</sup> | 300 | + | + | 1 |
| 2        | EAC       | + | + | + | + | + | 2 |
| 3        | SCC       | + | sm | 2000 | + | + | 3 |
| 4        | EAC       | + | + | + | + | + | 1 |
| 5        | EAC       | + | sm | 580 | + | + | 1 |
| 6        | EAC       | + | + | + | + | + | 1 |
| 7        | EAC       | + | + | + | + | + | 1 |
| 8        | EAC       | + | sm | 1200 | + | + | 1 |
| 9        | EAC       | + | sm | 1000 | + | + | 2 |
| 10       | EAC       | + | + | + | + | + | 2 |
| 11       | EAC       | + | sm | 465 | + | + | 2 |
| 12       | EAC       | + | sm | >500 | + | + | 4 |
| 13       | EAC       | + | sm | 650 | + | + | 2 |
| 14       | SCC       | + | sm | >200 | + | + | 2 |
| 15       | SCC       | + | Rx | m3<sup>c</sup> | + | + | 2 |
| 16       | SCC       | + | m3 | + | + | + | 2 |
| 17       | SCC       | + | Rx | + | + | + | 2 |
| 18       | SCC       | + | sm | 500 | + | + | 2 |
| 19       | SCC       | + | sm | 300 | + | + | 2 |
| 20       | SCC       | + | sm | 610 | + | + | 2 |
| 21       | SCC       | + | m3 | + | + | + | 2 |
| 22       | SCC       | + | sm | 500 | + | + | 2 |
| 23       | EAC       | + | sm | >500 | + | + | 2 |
| 24       | EAC       | + | sm | 900 | + | + | 2 |
| 25       | EAC       | + | sm | >500 | + | + | 3 |
| 26       | EAC       | + | sm | 1100 | + | + | 3 |
| 27       | EAC       | + | sm | 1400 | + | + | 2 |
| 28       | SCC       | + | sm | 1400 | + | + | 2 |
| 29       | SCC       | + | sm | 700 | + | + | 1 |
| 30       | EAC       | + | sm | >500 | + | + | 3 |

<sup>a</sup>Rx, vertical margin was positive in three patients, and impossible to assess.
<sup>b</sup>sm, submucosal invasion.
<sup>c</sup>lesion invading the muscularis mucosae.
EAC, early adenocarcinoma; SCC, squamous cell neoplasia.
At 1 year, overall survival, disease-free survival and cancer-specific survival were 63%, 70%, and 93% respectively.

In this group of nine patients (five transhiatal surgery and four gastrectomy), we observed six (67%) local residual tumors and no lymph node involvement in the esophagectomy specimen.

Deep-sm, deep submucosal invasion (⩾500 µm for EAC, and ⩾200 µm for SCC); EAC, esophageal adenocarcinoma; SCC, squamous cell carcinoma; Sup-sm, superficial submucosal invasion (<500 µm for EAC and <200 µm for SCC).

### Table 3. Histological characteristics of the esophagectomy specimens with residual cancer.

| Histological type | Positive vertical margins | Vertical invasion | Poor differentiation | Lymphovascular involvement | Surgical specimen | Recurrence | Time to recurrence (months) |
|-------------------|---------------------------|-------------------|----------------------|---------------------------|-------------------|------------|-----------------------------|
| EAC + M4          |                           |                   |                      |                           | pT1bN1M0          | Lung metastasis | 24                          |
| EAC M4 +          |                           |                   |                      |                           | pT1aN0M0          |             |                             |
| EAC + Sup-sm      |                           |                   |                      |                           | pT2N0M0           |             |                             |
| EAC Deep-sm       |                           |                   |                      |                           | pT1aN0M0          | Mediastinal lymph nodes | 33                          |
| EAC + Deep-sm     |                           |                   |                      |                           | pT1aN0M0          |             |                             |
| EAC + Deep-sm     |                           |                   |                      |                           | pT1aN0M0          |             |                             |
| EAC Deep-sm +     |                           |                   |                      |                           | pT1aN0M0          |             |                             |
| EAC Deep-sm + +   |                           |                   |                      |                           | pT3N0M0           |             |                             |
| SCC Not evaluable |                           |                   |                      |                           | pT1aN0M0          |             |                             |
| SCC Deep-sm       |                           |                   |                      |                           | pT0N1M0           |             |                             |

### Table 4. Postoperative complications according to the Clavien–Dindo classification.25

| IIIa | Early and severe postoperative complication (day 30) 15/30 | Late and severe postoperative complication (day 90) 2/30 |
|------|----------------------------------------------------------|--------------------------------------------------------|
| Surgical, endoscopic or radiologic intervention without general anesthesia | 3 | 3 |

| IIIb | Early and severe postoperative complication (day 30) 15/30 | Late and severe postoperative complication (day 90) 2/30 |
|------|----------------------------------------------------------|--------------------------------------------------------|
| Surgical, endoscopic or radiologic intervention with general anesthesia | 4 | 2 |

| IVa   | Early and severe postoperative complication (day 30) 15/30 | Late and severe postoperative complication (day 90) 2/30 |
|-------|----------------------------------------------------------|--------------------------------------------------------|
| Single organ dysfunction | 3 | 3 |

| IVb   | Early and severe postoperative complication (day 30) 15/30 | Late and severe postoperative complication (day 90) 2/30 |
|-------|----------------------------------------------------------|--------------------------------------------------------|
| Multi organ dysfunction | 3 | 2 |

| V     | Early and severe postoperative complication (day 30) 15/30 | Late and severe postoperative complication (day 90) 2/30 |
|-------|----------------------------------------------------------|--------------------------------------------------------|
| Death | 2 |  |
Furthermore, we observed one relapse (mediastinal lymph nodes; 11%), and two deaths (one for transhiatal surgery and one for gastrectomy; 22%).

**Discussion**

Esophagectomy is currently the standard therapeutic approach after noncurative endoscopic resection of early esophageal cancer. In this study, surgery provided a high curative rate with an overall and cancer-specific survival of 83% and 96% respectively. However, these results were associated with 43% severe morbidity and 7% perioperative mortality, while only four (13%) patients had an advanced pT status or lymph node metastases, actually indicating esophagogastrectomy. Indeed, 7 out of the 11 esophagectomy specimens containing neoplasia exhibited metachronous T1a lesions amenable to endoscopic treatment.

To our knowledge, eight retrospective studies have examined the outcomes of esophagectomy after endoscopic resection for superficial esophageal cancer (Table 5). The presence of lymph node metastases was low, ranging from 0% to 30%. The overall survival and disease-free survival were high, ranging from 85% to 100% and from 86% to 100% respectively, as also observed in our study. The perioperative mortality was poorly reported, with heterogeneous figures, ranging from 0% to 14%. Similarly, perioperative morbidity was scarcely reported, from 26% to 34%, and no long-term morbidity data are available (Table 5). Finally, the indication for surgery after endoscopic treatment was often unclear.

Zhang and colleagues recently performed a large retrospective study in patients with T1 SCC treated by esophagectomy (n = 274). The overall survival and cancer-specific survival were 89.1% and 92.6%, respectively, after a median follow up of 21 months. In another study involving patients with surgically resected T1 EAC, the 5-year overall survival and 3-year disease-free survival were 62% and 80% respectively. These data, in line with most surgical series confirm that surgical resection does not prevent late distant recurrences of T1 esophageal cancer, with or without previous endoscopic resection.

---

**Table 5.** Studies reporting outcomes of esophagectomy after noncurative endoscopic resection.

| Study                      | Patients, n = | pT0 | pN0 | Severe postoperative morbidity | Perioperative mortality | Follow up | DFS  | OS  |
|----------------------------|---------------|-----|-----|--------------------------------|-------------------------|-----------|------|-----|
| Hirasawa and colleagues32  | 8 EAC         | 0%  | 75% | NA                             | NA                      | 5 years   | 100% | 100%|
| Motoyama and colleagues33  | 17 SCC        | NA  | 70% | NA                             | 0%                      | 23 months | 100% | 100%|
| Hunt and colleagues28      | 7 EAC         | 14% | 100%| 29%                            | 14%                     | 2 years   | 86%  | 86% |
| Ikeda and colleagues27      | 15 SCC        | NA  | NA  | 26%                            | 13%                     | 3 years   | 88%  | 88% |
| Molena and colleagues29     | 23 EAC        | 52% | 84% | NA                             | 0%                      | 3 years   | 96%  | 92% |
| Plum and colleagues30       | 81 SCC 74 EAC | 31% | 93% | NA                             | 1.2%                    | 5 years   | 88%  | 85% |
| Suzuki and colleagues31     | 16 SCC 4 EAC  | NA  | NA  | NA                             | 0%                      | 2 years   | 100% | 100%|
| Wang and colleagues34       | 32 SCC 1 EAC  | 44% | 94% | 34%                            | 0%                      | 16 months | 88%  | 88% |

EAC, esophageal adenocarcinoma; DFS, disease-free survival; NA, not available; OS, overall survival; SCC, squamous cell carcinoma.
Given the complication rates recently reported in the Netherlands after esophageal or gastric resection for cancer,38 the complication rates after esophagectomy in our study can seem high. First, these results could be partly explained by a recruitment bias: indeed, a frequent reason for referring a patient for endoscopic resection is a poor performance status or the presence of multiple comorbid conditions making the patient a poor surgical candidate.39 As confirmed by Zhang and colleagues, the morbidity and mortality are largely impacted by the patient’s general condition, with morbidity rates ranging from 17.9% to 61.5% and mortality rates from 1.8% to 23.1%, depending on the patients’ performance status.40 Second, the surgical techniques were heterogenous. Minimally invasive esophagectomy was performed in only 40% of patients, and McKeown esophagectomy was performed in three patients (10% of cases), with important severe postoperative adverse events (2/3), whereas this surgical technique is typically dedicated to salvage surgery following chemoradiotherapy (CRT) in clinical practice.24 However, the numbers we found are in line with the findings of a recent national survey on 3286 esophagectomies across France finding a 7.9% in-hospital mortality after esophagectomy.41 The ESGE guidelines advise the consideration of CRT, along with surgery, after noncurative endoscopic resection.9 Several small retrospective studies reported the outcomes of patients treated by CRT in this setting.42–47 The disease-free and overall survival ranged from 73% to 100% and 64% to 100%, respectively. Furthermore, a large prospective Japanese study involving 102 patients with noncurative endoscopic resection of a T1 SCC treated by two different CRT protocols found this treatment approach to be feasible with a 89.7% progression-free survival, and over 20% severe toxicity.48 These findings, limited to SCC, indicate that CRT is an interesting approach with acceptable results and less treatment toxicity, particularly for patients with a poor performance status. Furthermore, CRT seemed to be less toxic than surgery: indeed, no treatment-related death was reported in any of these studies.42,44–48 To our knowledge, this is the first study to precisely report the outcomes of esophagectomy after a noncurative endoscopic resection, as defined by the ESGE. The limitations of our work include its retrospective design, a short follow up, a heterogeneous group in terms of histology and prognostic factors, a relatively small number of cases, and the absence of a control group of similar patients managed nonoperatively.

Conclusion
In this cohort, esophagectomy after noncurative endoscopic resection of early esophageal cancer allowed the resection of residual advanced cancer or lymph node metastases in 13% of cases, at the cost of 43% severe morbidity and 7% perioperative mortality. These data suggest that the patient’s general condition and the risk of lymph node involvement in superficial esophageal cancer should be carefully assessed in multidisciplinary meetings. Furthermore, the possibility of close follow up needs to be balanced with a highly morbid surgical management, in a setting where 63% of esophageal resections are tumor free.

Key summary
1. Summarize the established knowledge on this subject
   - Surgery is recommended in cases of noncurative endoscopic resection considering the risk of lymph node metastasis.
   - Surgery provides a high curative treatment rate after noncurative endoscopic resection.

2. What are the significant or new findings of this study?
   - Esophagectomy in this clinical setting allowed the resection of advanced residual cancer in 13% of cases and lymph node metastases in only 7% of cases.
   - Risk of lymph node metastasis should be weighed against the mortality and morbidity rates of esophagectomy.

Funding
The authors received no financial support for the research, authorship, and/or publication of this article.

Conflict of interest statement
The authors declare that there is no conflict of interest.

ORCID iD
Solène Dermine https://orcid.org/0000-0003-4848-115X
References

1. Gupta B and Kumar N. Worldwide incidence, mortality and time trends for cancer of the oesophagus. *Eur J Cancer Prev* 2017; 26: 107–118.

2. Guan C-T, Song G-H, Li B-Y, et al. Endoscopy screening effect on stage distributions of esophageal cancer: a cluster randomized cohort study in China. *Cancer Sci* 2018; 109: 1995–2002.

3. Merkow RP, Bilimoria KY, Keswani RN, et al. Treatment trends, risk of lymph node metastasis, and outcomes for localized esophageal cancer. *JNCI J Natl Cancer Inst* 2014; 106: dju133.

4. Probst A, Aust D, Märkl B, et al. Early esophageal cancer in Europe: endoscopic treatment by endoscopic submucosal dissection. *Endoscopy* 2014; 47: 113–121.

5. Tsuji Y, Nishida T, Nishiyama O, et al. Clinical outcomes of endoscopic submucosal dissection for superficial esophageal neoplasms: a multicenter retrospective cohort study. *Endoscopy* 2015; 47: 775–783.

6. Schölvinck D, Künzli H, Meijer S, et al. Management of patients with T1b esophageal adenocarcinoma: a retrospective cohort study on patient management and risk of metastatic disease. *Surg Endosc* 2016; 30: 4102–4113.

7. Pech O, May A, Manner H, et al. Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. *Gastroenterology* 2014; 146: 652–660, e1.

8. Takahashi H, Arimura Y, Masao H, et al. Endoscopic submucosal dissection is superior to conventional endoscopic resection as a curative treatment for early squamous cell carcinoma of the esophagus (with video). *Gastrointest Endosc* 2010; 72: 255–264, 264, e1–2.

9. Pimentel-Nunes P, Dinis-Ribeiro M, Ponchon T, et al. Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) guideline. *Endoscopy* 2015; 47: 829–854.

10. Evans JA, Early DS, Chandraskhara V, et al. The role of endoscopy in the assessment and treatment of esophageal cancer. *Gastrointest Endosc* 2013; 77: 328–334.

11. Bolischweiler E, Baldus SE, Schröder W, et al. High rate of lymph-node metastasis in submucosal esophageal squamous-cell carcinomas and adenocarcinomas. *Endoscopy* 2006; 38: 149–156.

12. Dubecz A, Kern M, Solymosi N, et al. Predictors of lymph node metastasis in surgically resected T1 esophageal cancer. *Ann Thorac Surg* 2015; 99: 1879–1886.

13. Leers JM, DeMeester SR, Oezcelik A, et al. The prevalence of lymph node metastases in patients with T1 esophageal adenocarcinoma: a retrospective review of esophagectomy specimens. *Ann Surg* 2011; 253: 271–278.

14. Yamashina T, Ishihara R, Nagai K, et al. Long-term outcome and metastatic risk after endoscopic resection of superficial esophageal squamous cell carcinoma. *Am J Gastroenterol* 2013; 108: 544–551.

15. Mariette C, Piessen G and Triboulet J-P. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. *Lancet Oncol* 2007; 8: 545–553.

16. Low DE, Alderson D, Cecconello I, et al. International consensus on standardization of data collection for complications associated with esophagectomy: Esophagectomy Complications Consensus Group (ECCG). *Ann Surg* 2015; 262: 286–294.

17. Messager M, Pasquer A, Duhamel A, et al. Laparoscopic gastric mobilization reduces postoperative mortality after esophageal cancer surgery: a French Nationwide study. *Ann Surg* 2015; 262: 817–822; discussion 822–823.

18. Takeuchi H, Miyata H, Gotoh M, et al. A risk model for esophagectomy using data of 5354 patients included in a Japanese nationwide web-based database. *Ann Surg* 2014; 260: 259–266.

19. McMillan RR, Berger A, Sima CS, et al. Thirty-day mortality underestimates the risk of early death after major resections for thoracic malignancies. *Ann Thorac Surg* 2014; 98: 1769–1775.

20. Hamouda A, Forshaw M, Rohatgi A, et al. Presentation and survival of operable esophageal cancer in patients 55 years of age and below. *World J Surg* 2010; 34: 744–749.

21. Ponchon T. A European Society of Gastrointestinal Endoscopy “abstract issue.” *Endoscopy* 2019; 51: S2–S3.

22. Dermine S, Barret M, Priexs C, et al. Impact of a dedicated multidisciplinary meeting on the management of superficial cancers of the digestive tract. *Endosc Int Open* 2018; 6: E1470–E1476.

23. Hulscher JBF, van Sandick JW, de Boer AGEM, et al. Extended transthoracic resection compared with limited transthiatal resection for adenocarcinoma of the esophagus. *N Engl J Med* 2002; 347: 1662–1669.
24. Ma G-W, Situ D-R, Ma Q-L, et al. Three-field vs two-field lymph node dissection for esophageal cancer: a meta-analysis. *World J Gastroenterol* 2014; 20:18022–18030.

25. Dindo D, Demartines N and Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg* 2004; 240: 205–213.

26. Wang W-P, Ni P-Z, Yang J-L, et al. Esophagectomy after endoscopic submucosal dissection for esophageal carcinoma. *J Thorac Dis* 2018; 10: 3253–3261.

27. Ikeda A, Hoshi N, Yoshizaki T, et al. Endoscopic submucosal dissection (ESD) with additional therapy for superficial esophageal cancer with submucosal invasion. *Intern Med* 2015; 54: 2803–2813.

28. Hunt BM, Louie BE, Schembre DB, et al. Outcomes in patients who have failed endoscopic therapy for dysplastic Barrett’s metaplasia or early esophageal cancer. *Ann Thorac Surg* 2013; 95: 1734–1740.

29. Molena D, Schlottmann F, Boys JA, et al. Esophagectomy following endoscopic resection of submucosal esophageal cancer: a highly curative procedure even with nodal metastases. *J Gastrointest Surg* 2017; 21: 62–67.

30. Plum PS, Hölscher AH, Pacheco Godoy K, et al. Prognosis of patients with superficial T1 esophageal cancer who underwent endoscopic resection before esophagectomy: a propensity score-matched comparison. *Surg Endosc* 2018; 32: 3972–3980.

31. Suzuki G, Yamazaki H, Aibe N, et al. Endoscopic submucosal dissection followed by chemoradiation therapy for superficial esophageal cancer: choice of new approach. *Radiat Oncol* 2018; 13: 246.

32. Hirasawa K, Kokawa A, Oka H, et al. Superficial adenocarcinoma of the esophagogastric junction: long-term results of endoscopic submucosal dissection. *Gastrointest Endosc* 2010; 72: 960–966.

33. Motoyama S, Jin M, Matsushashi T, et al. Outcomes of patients receiving additional esophagectomy after endoscopic resection for clinically mucosal, but pathologically submucosal, squamous cell carcinoma of the esophagus. *Surg Today* 2013; 43: 638–642.

34. Wang S, Huang Y, Xie J, et al. Does delayed esophagectomy after endoscopic resection affect outcomes in patients with stage T1 esophageal cancer? A propensity score-based analysis. *Surg Endosc* 2018; 32: 1441–1448.

35. Zhang Y, Ding H, Chen T, et al. Outcomes of Endoscopic Submucosal Dissection vs Esophagectomy for T1 esophageal Squamous Cell Carcinoma in a Real-World Cohort. *Clin Gastroenterol Hepatol*. 2019; 17: 73–81.

36. Pennathur A, Farkas A, Krasinskas AM, et al. Esophagectomy for T1 esophageal cancer: outcomes in 100 patients and implications for endoscopic therapy. *Ann Thorac Surg* 2009; 87: 1048–1054; discussion 1054–1055.

37. Stein HJ, Feith M, Bruecher BLD, et al. Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection. *Trans Meet Am Surg Assoc* 2005; 123: 260–269.

38. van der Werf LR, Busweiler LAD, van Sandick JW, et al. Reporting national outcomes after esophagectomy and gastrectomy according to the Esophageal Complications Consensus Group (ECCG). *Ann Surg*. Epub ahead of print 1 January 2019. DOI: 10.1097/SLA.000000000003210.

39. Cummings LC, Kou TD, Schlueter MD, et al. Outcomes after endoscopic versus surgical therapy for early esophageal cancers in an older population. *Gastrointest Endosc* 2016; 84: 232–240, e1.

40. Hodari A, Hammoud ZT, Borgi JF, et al. Assessment of morbidity and mortality after esophagectomy using a modified frailty index. *Ann Thorac Surg* 2013; 96: 1240–1245.

41. Degisors S, Pasquer A, Renaud F, et al. Are Thoracotomy and/or intrathoracic anastomosis still predictors of postoperative mortality after esophageal cancer surgery? A Nationwide Study. *Ann Surg* 2017; 266: 854–862.

42. Shimizu Y, Kato M, Yamamoto J, et al. EMR combined with chemoradiotherapy: a novel treatment for superficial esophageal squamous-cell carcinoma. *Gastrointest Endosc* 2004; 59: 199–204.

43. Canard J-M, Rahmi G, Palazzo L, et al. Évolution favorable à long terme des patients traités par résection muqueuse endoscopique pour une dysplasie de haut grade ou un cancer épidermoïde superficiel de l’œsophage. *Acta Endosc* 2011; 41: 193–199.

44. Hisano O, Nonoshita T, Hirata H, et al. Additional radiotherapy following endoscopic submucosal dissection for T1a-MM/T1b-SM esophageal squamous cell carcinoma improves locoregional control. *Radiat Oncol* 2018; 13.

45. Kawaguchi G, Sasamoto R, Abe E, et al. The effectiveness of endoscopic submucosal dissection followed by chemoradiotherapy for superficial esophageal cancer. *Radiat Oncol* 2015; 10: 31.
46. Mochizuki Y, Saito Y, Tsujikawa T, et al. Combination of endoscopic submucosal dissection and chemoradiation therapy for superficial esophageal squamous cell carcinoma with submucosal invasion. *Exp Ther Med* 2011; 2: 1065–1068.

47. Kam TY, Kountouri M, Roth A, et al. Endoscopic resection with adjuvant chemoradiotherapy for superficial esophageal squamous cell carcinoma: a critical review. *Crit Rev Oncol Hematol* 2018; 124: 61–65.

48. Minashi K, Nihei K, Mizusawa J, et al. Efficacy of endoscopic resection and selective chemoradiotherapy for stage I esophageal squamous cell carcinoma. *Gastroenterology* 2019; 157: 382–390, e3.